Additionally, African women displayed a notably higher risk of having cancers harbouring ERBB2 mutations (HR: 8.01; 95% CL: 2.41-26.68; p=0.001), and a lower risk of KRAS mutations (HR: 0.34; 95% CL: 0.13-0.89; p=0.027). This evidence concerns the gene KRAS and cancer.